$NEOG

Antique Stock Broking initiated coverage on Neogen Chemicals with a Buy rating and a target price of Rs.3,050, implying a 23% upside. The brokerage expects strong earnings growth driven by battery chemicals, with revenue, EBITDA, and PAT growing at CAGRs of 45%, 49%, and 87% respectively from FY26 to FY30. The stock has surged 64% in 6 months but faces execution and debt management risks.

NEOG reported Q3 revenue of $222.8M, beating estimates by 7%, and adjusted EPS of $0.08, beating by 50%. Adjusted EBITDA was $41.6M, an 18.7% margin. The company raised FY revenue guidance to $887.5M and EBITDA to $182M. Management highlighted commercial execution gains, innovation investments, and operational efficiency improvements.

Neogen (NEOG) reported Q2 revenue of $222.8M, up 6.5% YoY, beating estimates. CooperCompanies (COO) reported flat revenue, missing expectations. Abbott (ABT) reported $12.59B revenue, up 13% YoY, beating estimates. Stryker (SYK) reported $6.59B revenue, up 9.4% YoY, meeting expectations. Stocks reacted accordingly to the results.

Argus lowered its price target for Neogen Corporation to $12.00. The company develops, manufactures, and markets products for food and animal safety. Neogen is based in Lansing, Michigan.

CooperCompanies (COO) underperformed peers with weak results and guidance, stock down 14%. Baxter (BAX) beat estimates with 5.3% revenue growth, stock flat. Boston Scientific (BSX) missed guidance, stock down 6.2%. Abbott Labs (ABT) grew 13%, stock up 15.4%. Neogen (NEOG) beat estimates, stock down 2%. Market update discusses shifting investor concerns.

Neogen Chemicals' share price rose 8% on 14 October, adding to a 15% gain over three sessions. The rally, driven by strong buying and improved earnings, saw the stock reach record highs of Rs.2,748-2,778. Experts attribute the surge to the company's record June quarter results, with net profit up 138% year-on-year. Technical analysts note strong momentum and support levels around Rs.2,500-2,590.

Neogen Corp (NEOG) CEO Mikheal Nassif bought 505 shares at $11.95 each, totaling $6,034. The stock has risen 75% in a year, trading at $11.85 with a $2.56B market cap. Neogen's Q1 2027 earnings beat estimates, with $0.08 EPS on $222.8M revenue, and raised full-year guidance. Nassif disclaims beneficial ownership of the shares.

Neogen (NEOG) received an FDA warning over a contaminated veterinary product. The company's response and any follow-up actions will be key for investors to monitor. Additionally, investors should review the company's management structure and compensation packages.

Neogen Corp (NEOG) reported a net loss of $11.9M for Q2 2026, down from $36.3M net income in the same period last year. The company's GF Score is 66/100, with strengths in momentum and valuation but weaknesses in growth and financial strength. NEOG's stock is currently overvalued at $11.68 compared to its intrinsic value of $11.19. The company faces financial challenges but has opportunities in global food safety demand and international expansion.

Neogen (NEOG) reported Q1 FY27 revenue up 6.5% to $222.8M, raised full-year guidance, but shares fell 3.7%. Penguin Solutions (PENG) beat Q4 estimates, raised FY27 outlook, shares up 13.9%. Constellation Brands (STZ) topped Q2 estimates, shares up 3.5%. Hess Midstream (HESM) shares dropped 10.3% after restructuring deal with Chevron (CVX) and lowered 2027 outlook. SRX Global (SRXH) shares rose 4% after $1M stock deal to acquire CERo Therapeutics.